chr17-42904082-C-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000151.4(G6PC1):c.340+42C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00433 in 1,312,724 control chromosomes in the GnomAD database, including 147 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.018 ( 75 hom., cov: 31)
Exomes 𝑓: 0.0025 ( 72 hom. )
Consequence
G6PC1
NM_000151.4 intron
NM_000151.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.163
Publications
1 publications found
Genes affected
G6PC1 (HGNC:4056): (glucose-6-phosphatase catalytic subunit 1) Glucose-6-phosphatase (G6Pase) is a multi-subunit integral membrane protein of the endoplasmic reticulum that is composed of a catalytic subunit and transporters for G6P, inorganic phosphate, and glucose. This gene (G6PC) is one of the three glucose-6-phosphatase catalytic-subunit-encoding genes in human: G6PC, G6PC2 and G6PC3. Glucose-6-phosphatase catalyzes the hydrolysis of D-glucose 6-phosphate to D-glucose and orthophosphate and is a key enzyme in glucose homeostasis, functioning in gluconeogenesis and glycogenolysis. Mutations in this gene cause glycogen storage disease type I (GSD1). This disease, also known as von Gierke disease, is a metabolic disorder characterized by severe hypoglycemia associated with the accumulation of glycogen and fat in the liver and kidneys.[provided by RefSeq, Feb 2011]
G6PC1 Gene-Disease associations (from GenCC):
- glycogen storage disease due to glucose-6-phosphatase deficiency type IAInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia, Myriad Women’s Health
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BP6
Variant 17-42904082-C-T is Benign according to our data. Variant chr17-42904082-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 255351.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.0581 is higher than 0.05.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| G6PC1 | ENST00000253801.7 | c.340+42C>T | intron_variant | Intron 2 of 4 | 1 | NM_000151.4 | ENSP00000253801.1 | |||
| G6PC1 | ENST00000588481.1 | n.447C>T | non_coding_transcript_exon_variant | Exon 2 of 2 | 2 | |||||
| G6PC1 | ENST00000592383.5 | c.340+42C>T | intron_variant | Intron 2 of 4 | 2 | ENSP00000465958.1 | ||||
| G6PC1 | ENST00000585489.1 | c.340+42C>T | intron_variant | Intron 2 of 3 | 5 | ENSP00000466202.1 |
Frequencies
GnomAD3 genomes AF: 0.0179 AC: 2723AN: 152114Hom.: 75 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
2723
AN:
152114
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.00549 AC: 1379AN: 251074 AF XY: 0.00420 show subpopulations
GnomAD2 exomes
AF:
AC:
1379
AN:
251074
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00254 AC: 2953AN: 1160492Hom.: 72 Cov.: 16 AF XY: 0.00225 AC XY: 1331AN XY: 591412 show subpopulations
GnomAD4 exome
AF:
AC:
2953
AN:
1160492
Hom.:
Cov.:
16
AF XY:
AC XY:
1331
AN XY:
591412
show subpopulations
African (AFR)
AF:
AC:
1772
AN:
27422
American (AMR)
AF:
AC:
225
AN:
44316
Ashkenazi Jewish (ASJ)
AF:
AC:
237
AN:
24274
East Asian (EAS)
AF:
AC:
0
AN:
38256
South Asian (SAS)
AF:
AC:
6
AN:
80254
European-Finnish (FIN)
AF:
AC:
9
AN:
53264
Middle Eastern (MID)
AF:
AC:
26
AN:
5150
European-Non Finnish (NFE)
AF:
AC:
358
AN:
837120
Other (OTH)
AF:
AC:
320
AN:
50436
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
161
322
483
644
805
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
58
116
174
232
290
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.0179 AC: 2729AN: 152232Hom.: 75 Cov.: 31 AF XY: 0.0175 AC XY: 1304AN XY: 74428 show subpopulations
GnomAD4 genome
AF:
AC:
2729
AN:
152232
Hom.:
Cov.:
31
AF XY:
AC XY:
1304
AN XY:
74428
show subpopulations
African (AFR)
AF:
AC:
2496
AN:
41538
American (AMR)
AF:
AC:
128
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
AC:
29
AN:
3472
East Asian (EAS)
AF:
AC:
0
AN:
5178
South Asian (SAS)
AF:
AC:
0
AN:
4820
European-Finnish (FIN)
AF:
AC:
2
AN:
10598
Middle Eastern (MID)
AF:
AC:
3
AN:
294
European-Non Finnish (NFE)
AF:
AC:
41
AN:
68020
Other (OTH)
AF:
AC:
30
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
126
252
378
504
630
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
32
64
96
128
160
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
13
AN:
3478
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Apr 02, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA Benign:1
Apr 12, 2018
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.